Medtronic PLC (NYSE:MDT)

The valuation metrics exhibit a consistent pattern of significant initial contraction followed by a period of relative stabilization across all primary ratios. A substantial re-rating occurred between mid-2021 and mid-2022, characterized by a sharp decline in multiples, suggesting a market adjustment in the perceived growth or risk profile of the equity.

Price to Earnings (P/E) Ratio

A pronounced downward trend is observed from a peak of 46.71 in July 2021, falling to 22.61 by July 2022. Following this correction, the ratio entered a phase of volatility, oscillating between 21.15 and 30.94. The ratio concluded the period at 22.77, indicating a permanent shift to a lower earnings multiple compared to the 2021 levels.

Price to Operating Profit (P/OP) Ratio

The P/OP ratio mirrors the trajectory of the P/E ratio, starting at 38.83 in July 2021 and contracting to a low of 17.99 by October 2022. The metric remained largely range-bound between 18.00 and 22.00 for the subsequent years, eventually settling at 17.55 in July 2026, reflecting a compressed valuation relative to operating performance.

Price to Sales (P/S) Ratio

The revenue multiple shows a steady long-term decline from 5.74 in July 2021 to 3.17 in July 2026. While there were brief periods of stabilization, the general trend indicates that the market has assigned progressively lower value to each unit of sales over the observed timeframe, hitting a cyclical low of 2.79 in April 2026.

Price to Book Value (P/BV) Ratio

The P/BV ratio declined from 3.52 in July 2021 to a trough of 2.03 in October 2022. Unlike the other ratios, the P/BV showed a modest recovery trend in the latter half of the period, peaking again at 2.78 in October 2025 before ending at 2.37 in July 2026. This suggests that while the valuation compressed, the relationship between market price and book value remained more resilient than the earnings-based multiples.

Overall, the convergence of these ratios suggests a transition from a high-growth valuation premium in 2021 to a more conservative, value-oriented pricing model by 2026. The synchronization of the decline across P/E, P/OP, and P/S indicates a systemic reduction in the valuation multiple rather than an isolated change in a single financial metric.

Analysis of the valuation metrics from July 2021 through July 2026 reveals a significant contraction in the equity multiple alongside fluctuations in share price and a general strengthening of earnings per share toward the end of the period.

Price-to-Earnings (P/E) Ratio Trends

A pronounced downward adjustment in the P/E ratio is observed during the initial stages of the period. The ratio began at a high of 46.71 in July 2021 and experienced a rapid compression, reaching 22.61 by July 2022. Following this initial correction, the ratio entered a period of moderate volatility, fluctuating between a low of 21.15 in April 2026 and a peak of 30.94 in April 2023. The period concludes with a P/E of 22.77, indicating a more conservative valuation relative to earnings compared to the starting point.

Share Price Movement

The share price exhibited a strong downward trend in the first year, falling from 134.73 in July 2021 to 79.25 by October 2022. Subsequent movements were characterized by a cyclical pattern of recovery and correction. A notable recovery peak occurred in October 2025, with the price reaching 105.35, before settling at 93.10 in July 2026. The overall trajectory indicates a failure to return to 2021 highs, despite intermittent rallies.

Earnings per Share (EPS) Performance

EPS demonstrated greater resilience than the share price, characterized by an overall upward trajectory in the latter half of the period. After an initial rise to 3.92 in July 2022 and a subsequent dip to 2.72 in July 2023, earnings grew steadily. EPS reached its peak of 4.09 in July 2026, representing a significant increase from the 2.88 reported in July 2021.

Valuation Correlation

The divergence between the rising EPS and the volatile share price contributed to the observed P/E compression. While profitability improved over the five-year span, the market's willingness to pay a premium for those earnings decreased. The transition from a P/E of 46.71 to approximately 22.77 suggests a fundamental re-rating of the stock, moving from a high-growth or speculative premium to a more stable, value-oriented valuation.

The valuation metrics for Medtronic PLC exhibit a significant compression in the Price to Operating Profit (P/OP) ratio over the analyzed period, transitioning from a high-valuation environment in 2021 to a more stabilized, lower multiple by 2026.

Share Price Trends

A pronounced decline in share price is observed from July 2021, where the price stood at 134.73 US$, falling to a trough of 79.25 US$ by October 2022. Following this period, the price exhibited volatility with a general sideways trend, ranging primarily between 80 US$ and 90 US$. A temporary peak of 105.35 US$ occurred in October 2025, before the price adjusted to 93.10 US$ by July 2026.

Operating Profit per Share Growth

Operating profit per share demonstrated a consistent upward trajectory, contrasting the volatility of the share price. Starting at 3.47 US$ in July 2021, profit per share rose to 4.53 US$ by July 2022. After a period of relative stability between 4.01 US$ and 4.34 US$ from January 2023 through January 2024, a steady growth phase emerged, culminating in a peak of 5.31 US$ by July 2026.

P/OP Ratio Dynamics

The P/OP ratio experienced a sharp contraction during the first year of the period, dropping from 38.83 in July 2021 to 17.99 by October 2022. This decline was driven by the simultaneous decrease in share price and increase in operating profits. For the remainder of the period, the ratio largely stabilized within a range of 18.00 to 22.00, indicating a fundamental shift in how the market valued operating earnings. The ratio reached its lowest point of 15.70 in January 2026, reflecting the impact of peak operating profits relative to the share price at that time, before recovering slightly to 17.55 by July 2026.

The inverse relationship between the increasing operating profit per share and the overall declining or stagnant share price has resulted in a significantly lower valuation multiple. The data suggests that while the company has improved its operational efficiency and profitability per share, the market has recalibrated the P/OP multiple downward from its 2021 levels.

The Price to Sales (P/S) ratio exhibits a significant overall contraction over the analyzed period, transitioning from a high of 5.74 in July 2021 to 3.17 by July 2026. This downward trajectory is primarily characterized by a substantial decline in share price that decoupled from the consistent growth observed in revenue per share.

Share Price Volatility

A sharp decline is observed from July 2021, where the price stood at 134.73, falling to a low of 79.25 by October 2022. While the price experienced a moderate recovery peak of 105.35 in October 2024, it remained well below the initial 2021 levels, ending the period at 93.10.

Sales per Share Growth

Revenue generation per share demonstrates a steady and uninterrupted upward trend. Values increased incrementally from 23.48 in July 2021 to 29.35 by July 2026, indicating a consistent expansion in the company's top-line performance on a per-share basis.

P/S Ratio Interpretation

The P/S ratio underwent a rapid compression phase between July 2021 and October 2022, dropping from 5.74 to 3.42. Following this decline, the ratio entered a phase of relative stability, oscillating within a narrow range between 3.18 and 3.89 from January 2023 through October 2025. A notable dip to 2.79 occurred in January 2026, followed by a slight recovery to 3.17 in the final period.

The divergence between the rising sales per share and the fluctuating share price suggests a compression in the valuation multiple. The market's willingness to pay a premium for each dollar of sales decreased significantly from the 2021 peak and remained suppressed despite the improved revenue metrics.

The Price to Book Value (P/BV) ratio for the analyzed period exhibits a significant overall contraction followed by a phase of relative stabilization and moderate recovery. The valuation began at a peak of 3.52 in July 2021 and experienced a consistent decline throughout 2022, reaching a low of 2.03 by October 2022. This downward trajectory represents a substantial compression in the market's valuation of the company's net assets.

Price to Book Value (P/BV) Volatility

Following the initial decline, the P/BV ratio entered a period of consolidation between January 2023 and July 2025, generally fluctuating within a narrow range between 2.05 and 2.47. A secondary peak occurred in October 2025, where the ratio rose to 2.78, before settling at 2.37 by July 2026. This indicates a shift from a high-valuation environment to a more conservative valuation floor.

Book Value per Share (BVPS) Stability

The Book Value per Share remained remarkably stable throughout the period, oscillating within a tight band between 37.34 and 39.63. The absence of significant growth or contraction in BVPS suggests that the fluctuations in the P/BV ratio were driven almost exclusively by volatility in the market share price rather than changes in the underlying equity base.

Correlation Between Share Price and P/BV

A strong positive correlation is observed between the share price and the P/BV ratio. The sharp drop in share price from 134.73 in July 2021 to 79.25 in October 2022 directly mirrored the decline in the P/BV ratio. Similarly, the recovery of the share price to 105.35 in October 2025 corresponded with the increase in the P/BV ratio to 2.78, confirming that the valuation ratio acted as a direct reflection of market sentiment regarding the stock price.

In summary, the valuation metrics indicate a period of significant market correction in the early part of the series, transitioning into a stable range. The consistency of the book value suggests a steady internal asset base, while the P/BV fluctuations highlight varying degrees of market optimism and risk appetite over the five-year window.